Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company focused on MASH, Madrigal uses SEC reports to present detailed information on its financial performance, capital structure, risk factors, and material corporate events related to Rezdiffra (resmetirom) and its broader pipeline.
Investors can review current reports on Form 8-K where Madrigal announces quarterly and annual financial results, material financing arrangements, licensing agreements, and other significant events. Recent 8-K filings describe quarterly earnings releases, a senior secured credit facility with funds managed by Blue Owl Capital, and the use of proceeds to repay and terminate a prior loan agreement, as well as shareholder voting results from the annual meeting.
In addition to 8-Ks, users can access Madrigal’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) to study revenue from Rezdiffra, research and development spending on the MAESTRO clinical program and pipeline assets such as the licensed oral GLP-1 receptor agonist and ervogastat, and detailed risk factor disclosures. These filings also discuss regulatory considerations around MASH indications, ongoing Phase 3 outcomes trials, and forward-looking statements about the company’s strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from long filings, helping readers quickly understand changes in liquidity, debt covenants, operating expenses, and other important metrics without reading every page. Users can also track executive and director-related disclosures when Forms 3, 4, and 5 appear in the SEC stream, providing visibility into equity awards and other reportable transactions.
By combining real-time EDGAR updates with AI-generated insights, this page offers a practical way to follow how Madrigal’s clinical progress in MASH, commercialization of Rezdiffra, and financing decisions are reflected in its official SEC reporting.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of common stock related to taxes on equity compensation. On January 26, 2026, the issuer sold 647 shares of Madrigal common stock on her behalf at $492.42 per share to cover tax withholding obligations from the vesting of restricted stock units. The filing states this sale was automatic and not at her discretion.
After this transaction, Taub beneficially owned 452,704 shares directly and 655,540 shares indirectly through SQN LLC. She and her spouse are managing members of SQN LLC, and she disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals insiders filed a Rule 144 notice covering the planned sale of 647 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq Stock Market, with an aggregate market value of 310851.15. The 647 shares were acquired on 01/23/2026 via a restricted stock unit grant from the issuer, vesting the same day.
The notice also lists prior sales over the past three months. REBECCA A TAUB sold 2238 shares of common stock on 01/20/2026 for gross proceeds of 1098343.26, 18650 shares on 01/09/2026 for 9749391.94, and 18650 shares on 12/10/2025 for 10297573.26. Sales for PAUL A FRIEDMAN include 24800 shares on 01/09/2026 for 12963304.72 and 24800 shares on 12/10/2025 for 13694158.24. The signer represents they are not aware of undisclosed material adverse information about Madrigal’s operations.
An insider has filed a Rule 144 notice for the planned sale of 570 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of $273,856.50. The shares relate to restricted stock units acquired on 01/23/2026, and the planned sale date is 01/26/2026 on the NASDAQ. The filing notes that 22,711,420 shares of common stock were outstanding at the time of the notice.
The seller’s recent trading history includes Rule 10b5-1 sales for Carole A Huntsman on 11/21/2025 of 1,064 shares for $590,419.03 in gross proceeds and 894 shares for $492,567.18. By signing, the person for whose account the securities are to be sold represents that they do not know of any material adverse nonpublic information about the issuer’s operations.
Madrigal Pharmaceuticals’ General Counsel reports two stock sales. Kelley Shannon T, an officer of Madrigal Pharmaceuticals, reported selling 263 shares of common stock at
Madrigal Pharmaceuticals insider files to sell common stock. A Form 144 notice indicates an intention to sell 263 shares of Madrigal Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the Nasdaq Stock Market. These shares were acquired on 01/16/2026 via a restricted stock unit grant that vested on the same date. The filing notes that Madrigal Pharmaceuticals had 22,711,420 shares of common stock outstanding. Over the past three months, the same seller disposed of 429 shares of common stock on 01/20/2026 for gross proceeds of 215100.6. The signer represents that they are not aware of undisclosed material adverse information about the company.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of company stock primarily to cover taxes. On January 20, 2026, the issuer sold 2,238 shares of common stock on her behalf at $490.77 per share to satisfy tax withholding obligations tied to vesting restricted stock units, a process described as automatic and not at her discretion. Following this transaction, she directly held 453,351 shares of Madrigal Pharmaceuticals common stock. The filing also notes an additional 655,540 shares held indirectly through SQN LLC, an entity managed by Taub and her spouse, with Taub disclaiming beneficial ownership of those securities except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals insider files a Form 144 notice for a planned stock sale. The filing covers a proposed sale of 2238 shares of Madrigal common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an aggregate market value listed as 1122759.84 and 22711420 shares of common stock outstanding. The shares to be sold were acquired on 01/16/2026 via a restricted stock unit grant from the issuer, vesting the same day.
The notice also lists recent Rule 10b5-1 plan sales in the past three months. For Rebecca A. Taub, there were two sales of 18650 shares each on 12/10/2025 and 01/09/2026, with gross proceeds of 10297573.26 and 9749391.94. For Paul A. Friedman, there were two sales of 24800 shares each on the same dates, with gross proceeds of 13694158.24 and 12963304.72.
Madrigal Pharmaceuticals’ Chief Accounting Officer Rita Thakkar reported new equity awards. On January 15, 2026, she received 2,398 shares of common stock as a grant of restricted stock units at no cost. These units vest in four equal 25% installments on January 15 of 2027, 2028, 2029 and 2030, as long as she remains in service with the company on each vesting date.
She was also granted a stock option for 1,826 shares of common stock, likewise at no cost on the grant date. The option vests 25% of the shares on January 15, 2027, with the remaining 75% vesting in 6.25% increments on the last day of each successive three-month period, subject to continued service. After these grants, she directly holds 2,398 shares of common stock and 1,826 stock options.
Madrigal Pharmaceuticals, Inc. filed an initial ownership report for Chief Accounting Officer Rita Thakkar. The Form 3 states that no securities are beneficially owned, meaning the reporting person does not report holding any Madrigal common stock or derivative securities as of the event date. The filing is primarily administrative and does not describe any purchases, sales, or option grants.
Madrigal Pharmaceuticals insider files to sell 429 shares of common stock under Rule 144. The shares have an aggregate market value of $215,220.72 and are to be sold through Morgan Stanley Smith Barney LLC on or after an approximate sale date of 01/20/2026 on the NASDAQ exchange. The securities were acquired from the issuer on 01/16/2026 as restricted stock units, in the same amount of 429 shares. Madrigal Pharmaceuticals had 22,711,420 shares outstanding of common stock at the time referenced in the notice.